APC and colorectal carcinoma: In this respect, inhibiting Wnt/β-catenin signaling holds promise as a therapeutic intervention in CRC, as more than 94% of CRC cases exhibit mutations in at least one protein of this pathway, primarily the APC and FZD10, causing the pathway to be constitutively active [15].